Accelerate Diagnostics (NASDAQ:AXDX) Upgraded at StockNews.com

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Accelerate Diagnostics Stock Performance

NASDAQ AXDX opened at $1.89 on Thursday. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $5.78. The stock has a 50-day moving average of $1.77 and a 200 day moving average of $1.46. The company has a market capitalization of $47.33 million, a price-to-earnings ratio of -0.66 and a beta of 0.59.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently raised its position in Accelerate Diagnostics stock. Griffin Asset Management Inc. raised its position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the quarter. Griffin Asset Management Inc. owned 6.26% of Accelerate Diagnostics worth $1,615,000 as of its most recent SEC filing. 17.14% of the stock is currently owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.